Effects of recombinant human erythropoietin in normal humans
- PMID: 20807784
- PMCID: PMC3082090
- DOI: 10.1113/jphysiol.2010.195917
Effects of recombinant human erythropoietin in normal humans
Abstract
This review describes some of the physiological effects of recombinant human erythropoietin (EPO) in healthy humans. At the blood level EPO increases the arterial O(2) content not only by increasing red blood cell volume, but also by an equally important decrease in plasma volume. Well before that, EPO causes a prompt decrease in plasma levels of renin and aldosterone. Renal clearance studies suggest that EPO decreases renal proximal tubular reabsorption rate leading to activation of the tubuloglomerular feedback mechanism and a fall in glomerular filtration rate. Thus, treatment with EPO may result in suppression of endogenous EPO production through a decrease in intrarenal oxygen consumption. EPO elevates the arterial blood pressure even in healthy subjects. The receptor for EPO is present in many tissues. However, the functional effects of EPO in the skeletal muscle seem limited, and although it has been speculated that non-erythropoietic effects of EPO (angiogenesis, shift in muscle fibre types, cognitive effects) may be responsible for the increase in exercise performance, this has not been confirmed. EPO-induced haemodynamic effects call for careful monitoring during the administration period. The metabolic, hormonal and renal effects of EPO do not seem to range beyond physiologically acceptable limits and are reversible. Taken together, EPO seems safe to use for experimental purposes in healthy volunteers.
Figures

Similar articles
-
Erythropoietin down-regulates proximal renal tubular reabsorption and causes a fall in glomerular filtration rate in humans.J Physiol. 2011 Mar 15;589(Pt 6):1273-81. doi: 10.1113/jphysiol.2010.194241. Epub 2010 Aug 19. J Physiol. 2011. PMID: 20724370 Free PMC article.
-
Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume.J Physiol. 2007 Jan 1;578(Pt 1):309-14. doi: 10.1113/jphysiol.2006.122689. Epub 2006 Nov 9. J Physiol. 2007. PMID: 17095558 Free PMC article.
-
Strenuous training combined with erythropoietin induces red cell volume expansion-mediated hypervolemia and alters systemic and skeletal muscle iron homeostasis.Am J Physiol Regul Integr Comp Physiol. 2024 Nov 1;327(5):R473-R478. doi: 10.1152/ajpregu.00164.2024. Epub 2024 Sep 6. Am J Physiol Regul Integr Comp Physiol. 2024. PMID: 39241004
-
The relationship of erythropoietin and iron metabolism to red blood cell production in humans.Semin Oncol. 1994 Apr;21(2 Suppl 3):9-15. Semin Oncol. 1994. PMID: 8202725 Review.
-
Erythropoietic and non-erythropoietic functions of erythropoietin in mouse models.J Physiol. 2011 Mar 15;589(Pt 6):1259-64. doi: 10.1113/jphysiol.2010.196147. Epub 2011 Jan 31. J Physiol. 2011. PMID: 21282290 Free PMC article. Review.
Cited by
-
Neurostimulation, doping, and the spirit of sport.Neuroethics. 2021;14(Suppl 2):141-158. doi: 10.1007/s12152-020-09435-7. Epub 2020 May 16. Neuroethics. 2021. PMID: 34824648 Free PMC article.
-
Recombinant erythropoietin in humans has a prolonged effect on circulating erythropoietin isoform distribution.PLoS One. 2014 Oct 21;9(10):e110903. doi: 10.1371/journal.pone.0110903. eCollection 2014. PLoS One. 2014. PMID: 25335123 Free PMC article. Clinical Trial.
-
The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise.Pflugers Arch. 2021 Aug;473(8):1301-1313. doi: 10.1007/s00424-021-02577-4. Epub 2021 Jun 17. Pflugers Arch. 2021. PMID: 34142210 Free PMC article.
-
Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management.Cardiooncology. 2023 Dec 12;9(1):46. doi: 10.1186/s40959-023-00197-8. Cardiooncology. 2023. PMID: 38087384 Free PMC article. Review.
-
Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men.PLoS One. 2013;8(2):e56151. doi: 10.1371/journal.pone.0056151. Epub 2013 Feb 13. PLoS One. 2013. PMID: 23418527 Free PMC article. Clinical Trial.
References
-
- Allegra V, Martimbianco L, Vasile A. Lipid and apolipoprotein patterns during erythropoietin therapy: roles of erythropoietin, route of administration, and diet. Nephrol Dial Transplant. 1997;12:924–932. - PubMed
-
- Allegra V, Mengozzi G, Martimbianco L, Vasile A. Early and late effects of erythropoietin on glucose metabolism in maintenance hemodialysis patients. Am J Nephrol. 1996;16:304–308. - PubMed
-
- Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart M-T, Marion B, Bressolle F. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc. 1999;31:639–645. - PubMed
-
- Berglund B, Ekblom B. Effect of recombinant human erythropoietin treatment on blood pressure and some haematological parameters in healthy men. J Intern Med. 1991;229:125–130. - PubMed
-
- Birkeland KI, Stray-Gundersen JIM, Hemmersbach P, Hallen J, Haug E, Bahr R. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc. 2000;32:1238–1243. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous